{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:43:22Z","timestamp":1793731402215,"version":"4.6.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.pnpbp.2023.110787","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T09:09:18Z","timestamp":1684832958000},"page":"110787","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["The effects of sigma-1 agonist fluvoxamine on experimental induced tardive dyskinesia model in rats"],"prefix":"10.1016","volume":"126","author":[{"given":"Esra Toplu","family":"Uslu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Mengi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmas","family":"Beyazy\u00fcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliye","family":"\u00c7elikkol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakup","family":"Albayrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.pnpbp.2023.110787_bb0005","article-title":"Beneficial effects of the sigma-1 agonist fluvoxamine for tardive dyskinesia in patients with postpsychotic depressive disorder of schizophrenia: report of 5 cases","volume":"14","author":"Albayrak","year":"2012","journal-title":"Prim. Care Comp. CNS Disorder."},{"issue":"4","key":"10.1016\/j.pnpbp.2023.110787_bb0010","doi-asserted-by":"crossref","first-page":"417","DOI":"10.4306\/pi.2013.10.4.417","article-title":"Benefical effects of sigma-1 agonist fluvoxamine for tardive dyskinesia and tardive akathisia in patients with schizophrenia: report of three cases","volume":"10","author":"Albayrak","year":"2013","journal-title":"Psychiatry Investig."},{"key":"10.1016\/j.pnpbp.2023.110787_bb0015","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/978-3-319-50174-1_11","article-title":"Sigma-1 receptor agonists and their clinical implications in neuropsychiatric disorders","volume":"964","author":"Albayrak","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.pnpbp.2023.110787_bb0020","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cyto.2018.01.007","article-title":"Simultaneous presence of hypercoagulation and increased clot lysis time due to IL-1\u03b2, IL-6 and IL-8","volume":"110","author":"Bester","year":"2018","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.pnpbp.2023.110787_bb0025","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0024-3205(97)00228-2","article-title":"Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications","volume":"61","author":"Carlsson","year":"1997","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.pnpbp.2023.110787_bb0030","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.psc.2016.04.003","article-title":"Drug-induced extrapyramidal syndromes: implications for contemporary practice","volume":"39","author":"Caroff","year":"2016","journal-title":"Psychiat. Clin. North America"},{"issue":"Suppl. 4","key":"10.1016\/j.pnpbp.2023.110787_bb0035","first-page":"5","article-title":"Tardive dyskinesia: pathophysiology and animal models","volume":"61","author":"Casey","year":"2000","journal-title":"J. Clin. Psychiat."},{"key":"10.1016\/j.pnpbp.2023.110787_bb0040","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jns.2018.02.037","article-title":"Reprint of: clinical management of tardive dyskinesia: five steps to success","volume":"389","author":"Citrome","year":"2018","journal-title":"J. Neurol. Sci."},{"issue":"10","key":"10.1016\/j.pnpbp.2023.110787_bb0045","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1111\/j.1582-4934.2011.01374.x","article-title":"Unfolded proteins and endoplasmic reticulum stress in neurodegenerative disorders","volume":"15","author":"Doyle","year":"2011","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.pnpbp.2023.110787_bb0050","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1744-859X-9-17","article-title":"Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of five cases","volume":"9","author":"Furuse","year":"2010","journal-title":"Ann. General Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2023.110787_bb0055","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2174\/1871524910909030197","article-title":"Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship","volume":"9","author":"Hashimoto","year":"2009","journal-title":"Cent. Nerv. Syst. Agents Med. Chem."},{"key":"10.1016\/j.pnpbp.2023.110787_bb0060","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pneurobio.2012.09.001","article-title":"Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression","volume":"100","author":"Hashimoto","year":"2013","journal-title":"Prog. Neurobiol."},{"issue":"30","key":"10.1016\/j.pnpbp.2023.110787_bb0065","first-page":"3857","article-title":"Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals","volume":"12","author":"Hashimoto","year":"2006","journal-title":"Curr. Pharm. Des."},{"issue":"5","key":"10.1016\/j.pnpbp.2023.110787_bb0070","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2165\/00023210-200418050-00001","article-title":"Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders","volume":"18","author":"Hayashi","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pnpbp.2023.110787_bb0075","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejphar.2014.01.064","article-title":"Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells","volume":"727","author":"Ishima","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2023.110787_bb0080","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/B978-0-12-381328-2.00010-9","article-title":"Genetics of tardive dyskinesia","volume":"98","author":"Lee","year":"2011","journal-title":"Int. Rev. Neurobiol."},{"issue":"38","key":"10.1016\/j.pnpbp.2023.110787_bb0085","doi-asserted-by":"crossref","first-page":"15491","DOI":"10.1073\/pnas.1212899109","article-title":"Conditional ablation of brain-derived neurotrophic factor-TrkB signaling impairs striatal neuron development","volume":"109","author":"Li","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.pnpbp.2023.110787_bb0090","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/sj.cdd.4401778","article-title":"ER stress and neurodegenerative diseases","volume":"13","author":"Lindholm","year":"2006","journal-title":"Cell Death Differ."},{"issue":"7","key":"10.1016\/j.pnpbp.2023.110787_bb0095","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2174\/138161212799436476","article-title":"Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases","volume":"18","author":"Niitsu","year":"2012","journal-title":"Curr. Pharm. Des."},{"issue":"7","key":"10.1016\/j.pnpbp.2023.110787_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002558","article-title":"Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways","volume":"3","author":"Nishimura","year":"2008","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pnpbp.2023.110787_bb0105","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.schres.2005.11.021","article-title":"Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus","volume":"82","author":"Pillai","year":"2006","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.pnpbp.2023.110787_bb0110","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/SHK.0000000000001119","article-title":"Activation of Sigma-1 receptor by Cutamesine attenuates neuronal apoptosis by inhibiting endoplasmic reticulum stress and mitochondrial dysfunction in a rat model of asphyxia cardiac arrest","volume":"51","author":"Qin","year":"2019","journal-title":"Shock"},{"issue":"1","key":"10.1016\/j.pnpbp.2023.110787_bb0115","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1601-183X.2012.00858.x","article-title":"Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6\/2 mouse model of Huntington\u2019s disease","volume":"12","author":"Samadi","year":"2013","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.pnpbp.2023.110787_bb0120","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1146\/annurev.biochem.73.011303.074134","article-title":"The mammalian unfolded protein response","volume":"74","author":"Schr\u00f6der","year":"2005","journal-title":"Annu. Rev. Biochem."},{"issue":"2\u20133","key":"10.1016\/j.pnpbp.2023.110787_bb0125","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.schres.2004.08.004","article-title":"Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements","volume":"74","author":"Tan","year":"2005","journal-title":"Schizophr. Res."},{"issue":"9","key":"10.1016\/j.pnpbp.2023.110787_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023691","article-title":"Genome-wide identification of Bcl11b gene targets reveals role in brain-derived neurotrophic factor signaling","volume":"6","author":"Tang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.pnpbp.2023.110787_bb0135","doi-asserted-by":"crossref","DOI":"10.1177\/20451253221144347","article-title":"Tardive dyskinesia: understanding current challenges in diagnosis and treatment","volume":"13","author":"Taylor","year":"2023","journal-title":"Therapeut. Adv. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.pnpbp.2023.110787_bb0140","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/mds.25107","article-title":"Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis","volume":"27","author":"Teo","year":"2012","journal-title":"Movem. Disorder. : Off. J. Movem. Disorder Soc."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584623000738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584623000738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T20:04:12Z","timestamp":1759521852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584623000738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":28,"alternative-id":["S0278584623000738"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2023.110787","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effects of sigma-1 agonist fluvoxamine on experimental induced tardive dyskinesia model in rats","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2023.110787","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110787"}}